DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Huperzine-A is an investigational drug.
There have been 10 clinical trials for Huperzine-A. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2016.
The most common disease conditions in clinical trials are Alzheimer Disease, Schizophrenia, and Cognition Disorders. The leading clinical trial sponsors are Baylor College of Medicine, Spaulding Rehabilitation Hospital, and Neuro-Hitech.
Recent Clinical Trials for Huperzine-A
|Effects of Hearing Rehabilitative Interventions and Huperzine A on Presbycusis(Δ,kHz, dB,MMSE, AD)||Zhijun Bao||N/A|
|Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging||Shanghai Mental Health Center||Phase 4|
|Effects of Huperzine A in Treatment of Moderate to Severe TBI||Spaulding Rehabilitation Hospital||Phase 2|